Clinical Trial Update: Safety and Efficacy of MAT9001(Omega-3-pentaenoic Acid) in Subjects With Triglycerides ≥500 mg/dL and <2000 mg/dL [Phase 3]

View source ↗

Summary

Phase 3 trial of MAT9001 (Omega-3-pentaenoic Acid) in severe hypertriglyceridemia was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertriglyceridemia

Drugs mentioned

• MAT9001 (Omega-3-pentaenoic Acid)

Snippet

Sponsor: Matinas Biopharma, Inc | Conditions: Severe Hypertriglyceridemia | Phase 3 | Status: WITHDRAWN